JP2012513411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513411A5 JP2012513411A5 JP2011542581A JP2011542581A JP2012513411A5 JP 2012513411 A5 JP2012513411 A5 JP 2012513411A5 JP 2011542581 A JP2011542581 A JP 2011542581A JP 2011542581 A JP2011542581 A JP 2011542581A JP 2012513411 A5 JP2012513411 A5 JP 2012513411A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- activity
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 241000272525 Anas platyrhynchos Species 0.000 claims 2
- 241000272814 Anser sp. Species 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000287828 Gallus gallus Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241001494479 Pecora Species 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 101150045355 akt1 gene Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13975308P | 2008-12-22 | 2008-12-22 | |
| US61/139,753 | 2008-12-22 | ||
| PCT/US2009/069297 WO2010075443A1 (en) | 2008-12-22 | 2009-12-22 | Selective inhibitors of akt and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012513411A JP2012513411A (ja) | 2012-06-14 |
| JP2012513411A5 true JP2012513411A5 (cg-RX-API-DMAC7.html) | 2013-06-06 |
Family
ID=42288129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542581A Pending JP2012513411A (ja) | 2008-12-22 | 2009-12-22 | Ａｋｔの選択的阻害剤およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100168162A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2381779A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012513411A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010075443A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103509009A (zh) * | 2012-06-21 | 2014-01-15 | 中国科学院上海药物研究所 | 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途 |
| WO2016140973A1 (en) | 2015-03-02 | 2016-09-09 | Sanford-Burnham Medical Research Institute | Quinolinones as inhibitors of translation initiation complex |
| CN119390701B (zh) * | 2024-10-29 | 2025-11-25 | 中国药科大学 | 一种靶向降解pi3k蛋白的化合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050165053A1 (en) * | 2001-06-04 | 2005-07-28 | Cytovia, Inc. | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US20040171062A1 (en) * | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| CA2522431A1 (en) * | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
| EP2762475A1 (en) * | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
| WO2005113762A1 (en) * | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| CA2600745A1 (en) * | 2005-03-03 | 2006-09-08 | The Burnham Institute For Medical Research | Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby |
-
2009
- 2009-12-22 JP JP2011542581A patent/JP2012513411A/ja active Pending
- 2009-12-22 WO PCT/US2009/069297 patent/WO2010075443A1/en not_active Ceased
- 2009-12-22 EP EP09835795A patent/EP2381779A4/en not_active Withdrawn
- 2009-12-22 US US12/645,313 patent/US20100168162A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009298801A5 (cg-RX-API-DMAC7.html) | ||
| Bigaud et al. | Second generation S1P pathway modulators: research strategies and clinical developments | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2019519519A5 (cg-RX-API-DMAC7.html) | ||
| FI3721882T3 (fi) | Aineenvaihduntahäiriöiden hoito hevoseläimissä | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2016536286A5 (cg-RX-API-DMAC7.html) | ||
| JP2013067643A5 (cg-RX-API-DMAC7.html) | ||
| JP2016539921A5 (cg-RX-API-DMAC7.html) | ||
| EP2478901A3 (en) | Neurogenic compounds | |
| JP2008535785A5 (cg-RX-API-DMAC7.html) | ||
| JP2014533272A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530706A5 (cg-RX-API-DMAC7.html) | ||
| BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente | |
| JP2016513124A5 (cg-RX-API-DMAC7.html) | ||
| JP2012513411A5 (cg-RX-API-DMAC7.html) | ||
| WO2014052780A3 (en) | Compositions and methods of use of an inappetance-controlling compound | |
| JP2015513396A5 (cg-RX-API-DMAC7.html) | ||
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| KR20120085353A (ko) | 가금류, 가축의 조류독감 및 호흡기 질환 치료제 및 예방제 | |
| MX2013006353A (es) | Metodos y composiciones utiles para promover el sueño en animales. | |
| RU2013150192A (ru) | Метапневмовирус птиц в онколизисе | |
| JP2015524474A5 (cg-RX-API-DMAC7.html) | ||
| WO2012009542A3 (en) | Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration | |
| WO2014011949A3 (en) | Neuroprotective cb2 receptor agonists |